Nous utilisons des cookies pour améliorer votre expérience sur notre site. En parcourant ce site Web, vous acceptez notre utilisation des cookies.
News - Cellvizio - 22 oct. 2019

Evaluer la pneumologie interventionnelle comme prochain facteur de croissance (en anglais)

Provided below is a newly published company note authored by goetzpartners securities Limited discussing our 510(k) clearance for the use of Cellvizio in the field of interventional pulmonology. 

This report highlights how interventional pulmonology represents a promising commercial opportunity based on (1) a large market with a vast clinical need, (2) Cellvizio's unique ability to facilitate biopsy guidance and in vivo characterization, and (3) first mover advantage with a well differentiated product that is compatible with conventional bronchoscopes, emerging endoluminal robotic platforms as well as existing advanced navigational bronchoscopy platforms.


Disclaimer
Please note that this Equity Research publication is for Institutional Investor / Professional Investor use only and is not intended for Retail / Private client use. Any opinions, estimates or forecasts regarding Mauna Kea Technologies, S.A.’s performance made by goetzpartners securities Limited analysts are theirs alone and do not represent opinions, forecasts or predictions of Mauna Kea Technologies, S.A. or its management.